Diğer Yayınlar KoleksiyonuOther Publications Collectionhttps://hdl.handle.net/20.500.12511/41752024-03-28T20:33:20Z2024-03-28T20:33:20ZArtificial intelligence in breast imaging: Opportunities, challenges, and legal–ethical considerationsDurur Subaşı, IrmakÖzçelik, Ş. Barışhttps://hdl.handle.net/20.500.12511/123862024-03-21T08:34:55Z2023-01-01T00:00:00ZArtificial intelligence in breast imaging: Opportunities, challenges, and legal–ethical considerations
Durur Subaşı, Irmak; Özçelik, Ş. Barış
This review explores the transformative impact of artificial intelligence (AI) in breast imaging, driven by a global rise in breast cancer cases. Propelled by deep learning techniques, AI shows promise in refining diagnostic processes, yet adoption rates vary. Its ability to manage extensive datasets and process multidi-mensional information holds potential for advancing precision medicine in breast cancer research. However, integration faces challenges, from data-related obstacles to ensuring transparency and trust in decision-mak-ing. Legal considerations, including the formation of AI teams and intellectual property protection, influence health care’s adoption of AI. Ethical dimensions underscore the need for responsible AI implementation, emphasizing autonomy, well-being, safety, transparency, and accessibility. Establishing a robust legal and ethical framework is crucial for conscientiously deploying AI, ensuring positive impacts on patient safety and treatment efficacy. As nations and organizations aspire to engage in global competition, not merely as consumers, the review highlights the critical importance of developing legal regulations. A comprehensive approach, from AI team formation to end-user processes, is essential for navigating the complex terrain of AI applications in breast imaging. Legal experts play a key role in ensuring compliance, managing risks, and fostering resilient integration. The ultimate goal is a harmonious synergy between technological advancements and ethical con-siderations, ushering in enhanced breast cancer diagnostics through responsible AI utilization.
2023-01-01T00:00:00ZData-driven medicine: The promise and potential of clinical decision support systemsTariq, SabaTariq, Sundushttps://hdl.handle.net/20.500.12511/123832024-03-21T06:59:24Z2024-01-01T00:00:00ZData-driven medicine: The promise and potential of clinical decision support systems
Tariq, Saba; Tariq, Sundus
Patient safety is one of the most important factors involved in any health care policy. The idea of evidence-based medicine has emerged as the dominant paradigm in clinical practice, influencing our current understanding of medicine. Clinical decisions are based on accumulated scientific information in order to provide the best possible care, enhance patient outcomes, and save expenses.
2024-01-01T00:00:00ZInfant and young child feeding in emergencies: A narrative reviewBilgin, Demet DenizKarabayır, Nalanhttps://hdl.handle.net/20.500.12511/123792024-03-20T07:38:13Z2024-01-01T00:00:00ZInfant and young child feeding in emergencies: A narrative review
Bilgin, Demet Deniz; Karabayır, Nalan
In emergencies, infants and young children are at risk of morbidity and mortality, which is increased by malnutrition. Environmental factors, food insecurity, household needs, misconceptions regarding breastfeeding, uncontrolled distribution of breast-milk substitutes, and psychological trauma make it difficult to implement proper feeding practices during disasters. Breastfeeding reduces the risk of infectious diseases and mortality in emergencies and is the safest way of feeding. Therefore, breastfeeding should be supported and promoted under all circumstances. When breastfeeding is not possible, relactation, wet nursing, or donor human milk should be considered as alternatives. If these options are not feasible, infant formula should be used. Formula should be provided only for infants in need, based on individual assessment. Donations of breast-milk substitutes should not be accepted; when needed, the procurement and distribution should be conducted by a single center under strict control, adhering to the requirements of the Code and Codex Alimentarius. Education and support should be provided to the family for the safe use of formulas. For infants older than 6 months, appropriate complementary feeding should be started. Complementary foods should contain nutrients that support the growth and development of infants, and they should be stored, prepared, and served safely. In conclusion, nutrition of infants and young children should be given priority in disasters as part of all emergency interventions. Determining the infants needs and ensuring proper nutrition, overcoming environmental challenges, and supporting parents will reduce nutrition-related risks and protect the health and well-being of infants and young children in emergencies.
2024-01-01T00:00:00ZOverview of current pharmacotherapeutic options in benign prostatic hyperplasiaKoudonas, AntoniosAnastasiadis, AnastasiosTsiakaras, StavrosLangas, GeorgiosSavvides, EliophotosMykoniatis, IoannisMemmos, DimitriosBaniotis, PanagiotisVakalopoulos, Ioannisde la Rosette, Jean J. M. C. H.Dimitriadis, Georgioshttps://hdl.handle.net/20.500.12511/122752024-02-15T05:54:52Z2023-01-01T00:00:00ZOverview of current pharmacotherapeutic options in benign prostatic hyperplasia
Koudonas, Antonios; Anastasiadis, Anastasios; Tsiakaras, Stavros; Langas, Georgios; Savvides, Eliophotos; Mykoniatis, Ioannis; Memmos, Dimitrios; Baniotis, Panagiotis; Vakalopoulos, Ioannis; de la Rosette, Jean J. M. C. H.; Dimitriadis, Georgios
Introduction: Benign prostatic hyperplasia (BPH) represents the histological entity of prostate cell proliferation, which inflicts a gradually increasing obstruction of the bladder outlet and is accompanied by a progressing manifestation of lower urinary tract symptoms (LUTS). BPH management algorithm includes conservative measures, pharmaceutical agents, and surgical procedures. Areas covered: A comprehensive literature review was performed using PubMed, Scopus, and Google Scholar databases to identify publications written in English, analyzing BPH pharmaceutical treatment. The search was conducted from January 2000 to January 2023. Six main drug classes can be administered, either as monotherapy or in combination. Furthermore, the authors provide current direction of research on future medications, which focuses on a more etiological interference to the BPH pathophysiological mechanism. Expert opinion: The available medications represent an effective first-line step of BPH/LUTS therapy. Currently, the administration of BPH medications is tailored to patient/disease characteristics and entails long-time adherence to therapy. The emergence of new surgical modalities, which combine significantly lower morbidity compared to standard procedures and more durable effects than the available medications, seems to challenge the current treatment algorithm. More direct comparisons and the increasing experience with these surgical modalities will delineate the switch points between various therapy levels along the BPH management sequence.
2023-01-01T00:00:00Z